Here’s What’s Really Happening with Canopy Growth Corp (TSX:WEED)

Canopy Growth Corp (TSX:WEED)(NYSE:CGC) has started coming down again after two major dips in the last year, but is it time to buy, sell, or hold on for dear life?

| More on:
Man holding magnifying glass over a document

Image source: Getty Images.

You’re reading a free article with opinions that may differ from The Motley Fool’s premium investing services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn moresdf

If you’re like me and have been watching Canopy Growth (TSX:WEED)(NYSE:CGC) over the past year, you’re probably pretty dizzy by now.

The stock was on such a great trend, reaching the $70 range, when October hit — and hit hard. As you’re probably aware, share dropped to more than 50% where they once were, leaving investors scrambling.

Then things started to look up again. The stock has rebounded quite a bit, even hitting that $70 mark again. But since then it’s gone back done to just under $60 per share at the time of writing this article. I mean, look at its performance in the last year; if this is a roller-coaster ride, it’s definitely one that’ll make you nearly nauseous.

WEED Chart

WEED data by YCharts.

So, what the heck is going on?

Trying to keep momentum

If you were to look at Canopy’s news section on its website, you’d be even more in the dark on why this company’s stock isn’t on a steady trend upwards. Every few days, the company makes some sort of announcement in the hopes to help shares.

In the past week alone, the company announced a multi-year extraction agreement with HollyWeed Manufacturing & Extracts Inc., acquired AgriNextUSA, a hemp enterprise that will help Canopy expand in the U.S., and “received a cultivation licence from Health Canada for its facility in Fredericton, New Brunswick.” That’s a lot of good news.

On top of those announcements is the company’s latest quarterly earnings report, where it announced tremendous sales gains. There’s also the company’s 5.6 million square feet of cultivation space that will produce more than 500,000 kilograms of cannabis at peak capacity. And, of course, we can’t forget the $5 billion deal with Constellation Brands that’ll help Canopy expand over the long term.

Keyword: long-term

While there’s a lot of good news being reported, it doesn’t really help investors right this minute. Canopy is in the midst of creating a base: acquiring companies, beginning its expansion into the U.S., expanding internationally, creating brand power, and producing as much cannabis as possible.

It’s completely unclear when all of this will be done. It takes a long time to receive licences from both Canada and the U.S. There’s likely going to be a lot of promises of production that then fall short. And while acquiring the mom-and-pop pot shops is all well and good, that costs money. It’s going to take a lot of money to buy out everyone that could get in Canopy’s way, from a popular shop in Denver to a thriving hemp producer in Alberta.

So, if you own this stock or are wondering whether today’s price is near the bottom, what should you do?

Buy? Sell? Hold?

You’ll notice below that I own this stock, so I obviously want it to do well. However, I’m also looking for the best opportunity to either get out at top dollar or buy more to make more.

To be honest, I see this stock going down even further. While the company is reinvesting in its business, that means it’s draining its (albeit immense) cash supply. Over the next year or so, I wouldn’t be surprised if the company started reporting a few losses while they get themselves set up with their ambitious goals.

However, I’m definitely not selling any time soon. When I bought Canopy, it was as an investment. An exciting investment, yes, with some major moves at the beginning. But now that the dust has settled, I believe this stock has the chance to be the best.

With that in mind, I’ll be holding onto this stock for years to come and waiting for another opportunity to buy a few more shares when those earnings reports come in.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Amy Legate-Wolfe owns shares of Canopy Growth.

More on Cannabis Stocks

Cannabis smoke
Cannabis Stocks

Canopy Growth Stock: Is Now a Good Time to Invest?

The road ahead is highly uncertain for Canopy Growth, as the stock is plagued with losses and seemingly unsurmountable industry…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

TLRY Stock: Should You Invest Now?

TLRY is a Canadian cannabis stock which is trading 91% below record highs. Let's see if you should own TLRY…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

Is Tilray Stock a Buy in February 2023?

Despite the volatile cannabis sector, Tilray could be a superb buy for long-term investors.

Read more »

Young woman sat at laptop by a window
Cannabis Stocks

Is SNDL Stock a Buy in February 2023?

SNDL is a beaten-down cannabis stock. While its revenue growth is exceptional, a weak balance sheet has driven stock prices…

Read more »

A cannabis plant grows.
Cannabis Stocks

TLRY Stock: Here’s What’s Coming in 2023

Tilray Inc. (TSX:TLRY) is geared up for big growth this decade and looks like one of the top cannabis stocks…

Read more »

A person holds a small glass jar of marijuana.
Cannabis Stocks

Canopy Growth Stock: Here’s What’s Coming in 2023

Canopy Growth stock has made a lot of new moves in the last few months, but where is the company…

Read more »

A cannabis plant grows.
Cannabis Stocks

Better Cannabis Buy: Canopy Growth Stock or Tilray?

Only two TSX weed stocks can deliver substantial returns in the highly anticipated growth of the global cannabis market.

Read more »

Medicinal research is conducted on cannabis.
Cannabis Stocks

Is Tilray Stock a Buy in January 2023?

Tilray stock has lost 50% of its value in the last 12 months, in line with its peers.

Read more »